Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

More on Regeneron Pharma (REGN +1.6%) Q4: swings to net profit of $470M from a net loss of...

  • Thursday, February 14, 8:23 AM ET
    More on Regeneron Pharma (REGN +1.6%) Q4: swings to net profit of $470M from a net loss of $53.4M as sales more than triple, with its Eylea eyecare product bringing in $276M. Earnings also include $127M in collaboration revenues and a non-cash tax benefit of $336M. Forecasts 2013 Eyelea sales of $1.2-1.3B in the U.S. Partner Bayer has started to launch the product overseas. (PR)
Track new comments on this story

This news story has 1 comment:

  •  
    As someone who has closely invested in and watched REGN over almost 20 years, I am thrilled but not surprised that this innovative, disciplined, and well-managed company has begun to reap the fruits of its labors. While there are many challenges ahead, and granted I am not an expert in the field of biotech, I do believe, based on sound data about this company and its products, that this is only the beginning of a very, very, good ride.
    14 Feb, 08:42 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)
Latest Earnings Articles
More Latest Articles »